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1. Summary 
According to the WHO surveillance report in 2014 antimicrobial resistance is an 
increasingly serious threat to global public health. Infections are becoming harder or 
impossible to control; the risk of infections spreading to others is increased; illness 
and hospital stays are prolonged, with added economic and social costs. The 
problem is so serious that it threatens the achievements of modern medicine.  
Lately the use of cold atmospheric plasma (CAP), a partly ionized gas at room 
temperature and pressure, has developed into an innovative field in medicine and 
hygiene. Due its antimicrobial properties cold atmospheric plasma aroused attention 
in dermatology; possible application fields are wound disinfection and the treatment 
of other pathogen-caused skin diseases. However, this technology is rather novel 
and the medical and hygiene community has to be convinced that CAPs are safe, 
controllable and efficient. The motivation of this study was therefore to find a 
“therapeutic window” where bacteria are inactivated and human skin is not damaged. 
For this purpose, the bactericidal efficacy of CAP in this work was examined in 
more true-to-life conditions than previous studies. The bactericidal effect of CAP was 
examined in solution, as the wound environment is rather wet. High reduction rates of 
E.coli of more than 5 log steps were achieved in less than 3 minutes of CAP 
application. 
Besides achieving high bacterial reductions it is further important to investigate 
patient safety i.e. if CAP can be applied to human skin or other eukaryotic cells in 
general. By carrying out the hypoxanthine-guanine phosphoribosyl transferase 
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(HPRT) assay the mutagenic potential of the used CAP source was therefore 
investigated. 
CAP produced by the used device did not evoke mutations beyond naturally 
occurring spontaneous mutations. In addition to that, the impact of CAP treatment on 
the cell biology of primary human dermal fibroblasts including proliferation, cell cycle 
distribution and migration was examined. The results show that CAP application only 
slightly inhibited cell proliferation and migration and that a cell cycle arrest was only 
detectable for high dosages.  
The data of this work clearly reveal CAP as a promising candidate for efficient and 
safe wound disinfection. This paves the way for new medical treatments and the 
possibility in future to use designed plasma in several application fields. 
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2. Zusammenfassung 
Laut des Überwachungsberichts der WHO im Jahr 2014 ist Antibiotikaresistenz 
eine zunehmend ernste Bedrohung für die globale öffentliche Gesundheit. Es wird 
immer schwieriger bis unmöglich Infektionen zu kontrollieren; das Risiko einer 
Ausbreitung von Infektionen auf andere ist erhöht; zusätzlich zu wirtschaftlichen und 
sozialen Kosten verlängert sich die Dauer von Krankheiten und 
Krankenhausaufenthalten. Das Problem ist so gravierend, dass all die 
Errungenschaften der modernen Medizin bedroht sind. 
In den letzten Jahren hat sich die Verwendung von kaltem Plasma bei 
Atmosphärendruck (CAP), einem teilweise ionisierten Gas, zu einem innovativen 
Bereich der Medizin und Hygiene entwickelt. Aufgrund der bakteriziden Wirkung von 
CAP erregte es Aufmerksamkeit in der Dermatologie; mögliche Einsatzgebiete sind 
Wunddesinfektion und die Behandlung von anderen, von Pathogenen 
hervorgerufenen Hautkrankheiten. Diese Technologie ist jedoch eher neu und muss 
daher erst die Medizin- und Hygienegemeinschaft von seiner Sicherheit, 
Kontrollierbarkeit und Effizienz überzeugen. Die Motivation dieser Arbeit war 
deshalb, ein therapeutisches Fenster zu finden, in dem Bakterien abgetötet werden 
und menschliche Haut nicht geschädigt wird.  
Zu diesem Zweck wurde in dieser Arbeit die bakterizide Wirksamkeit unter  
Bedingungen untersucht, die realitätsnaher waren als die in vorherigen Studien. Der 
antibakterielle Effekt wurde in Lösung untersucht, da Wunden auch eine nasse 
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Umgebung darstellen. Hohe Reduktionsraten von E.coli von mehr als 5 log Stufen 
konnten in weniger als 3 Minuten Plasmabehandlung erzielt werden. 
Genauso wichtig wie hohe Reduktionsraten ist die Untersuchung der 
Patientensicherheit, d.h. ob CAP auf menschlicher Haut oder generell auf 
eukaryotischen Zellen angewendet werden kann. Mit der Durchführung des 
Hypoxanthin-guanin Phosphoribosyl Transferase (HPRT) Tests wurde das deswegen 
mutagene Potential von CAP untersucht. Das von dem hier genutzten Gerät 
produzierte Plasma rief keine Mutationen zusätzlich zu den spontanen, natürlich 
auftretenden Mutationen hervor.  
Zusätzlich dazu wurde der Einfluss von CAP auf die Zellbiologie von menschlichen, 
primären Haut Fibroblasten hinsichtlich Proliferation, Zellzyklusverteilung und 
Migration untersucht. Die Ergebnisse zeigen nur eine geringfügig verminderte 
Zellproliferation und –migration und dass der Zellzyklusarrest nur für hohe Dosen 
nachweisbar war. 
Die Daten dieser Arbeit weisen deutlich darauf hin, dass CAP ein 
vielversprechender Kandidat für effiziente und sichere Wunddesinfektion ist. Es 
ebnet den Weg für neue medizinische Behandlungsmethoden und die Möglichkeit, 
designtes Plasma zukünftig in weiteren Anwendungsbereichen zu verwenden. 
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3. Introduction 
As history shows, new tools are often found by accident. Since 99% of the visible 
universe consists of plasma, all its forms are common objects of investigation in 
space research. While hot plasma has been used for years to sterilize surgical 
instruments it is limited to thermo-stable materials and environments. After it was 
possible to generate plasma at atmospheric pressure and under ambient conditions, 
plasma physicists like Prof. Laroussi had the idea to examine the effects of cold 
atmospheric plasma (CAP) on living bacteria. [1] They found that CAP has very 
strong antibacterial effects. In 2005 the research field “plasma medicine” was born 
when the group of Prof. Morfill at the MPE started the first clinical study worldwide 
with CAP on human wounds. Cold atmospheric plasma (CAP) is an upcoming 
technology due to its broad antibacterial properties, [2-10] the probable lack of 
resistance against it [11, 12] and the potential to preserve the functionality of the 
surrounding human cells. [13-16] 
3.1 Plasma 
In medicine plasma normally describes blood plasma. But plasma in this context is 
the so called fourth state of matter. Sir William Crookes, an English physicist, first 
described it in 1879. In 1929, the term “plasma” was first applied to ionized gas by 
Dr. Irving Langmuir, an American chemist and physicist [17]. “Ionized” means that at 
least one electron is not bound to an atom or molecule, converting the atoms or 
molecules into positively charged ions. As temperature increases, molecules become 
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more energetic and the state changes from solid over liquid to gaseous and finally to 
plasma, which justifies the title “fourth state of matter”. [18] 
 
Figure 1: The four states of matter. By addition of energy matter is transformed from solid over 
liquid and gas to plasma. 
The free electric charges – electrons and ions – make plasma electrically 
conductive, internally interactive, and strongly responsive to electromagnetic fields. 
An ionized gas - both natural and artificially generated - is usually called plasma 
when it contains well balanced numbers of negative and positive charged particles, 
which means quasi-neutral. Neutral particles may be present as well. The relative 
number of ions and atoms (the ratio of density of major charged species to that of 
neutral gas, 𝑛𝑖
𝑛𝑎
) is called the degree of ionization. The ionization energy, or ionization 
potential, is typically specified in electron volts (eV) and refers to the energy required 
to remove a single electron from a single atom or molecule. [18] 
High-temperature plasma is an established method to sterilize equipment or to 
remove/destruct, cut and cauterize tissue and most recently for cosmetic 
reconstruction of tissue. In the past years, researchers found out, that, due to 
reactive species, charging reactions, ultraviolet radiation (UVR), optical and infrared 
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emissions and heat, plasma has bactericidal and fungicidal effects. [19, 20] It depicts 
a practicable tool in application areas where temperature is not an issue. But when it 
comes to living tissues and thermo labile materials temperature is a limiting factor. 
And above all, vacuum chambers are not practicable in clinics or everyday life. The 
challenge was therefore to bring the plasma, with all its benefits, down to room 
temperature and atmospheric pressure. 
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3.2 Cold atmosphere pressure plasma (CAP) 
In the last two decades research has succeeded in creating cold plasma at 
atmospheric pressure. Cold atmosphere pressure plasma (CAP) has similar benefits 
as high-temperature plasma with all its characteristics, but without the enormous heat 
production.  
Usually very high temperatures and high energy input are needed for ionization. 
The electron temperature is relatively high; therefore plasma is referred to as being 
"hot”. Sometimes the term "cold plasma" is used when the temperatures of the 
present ions and neutrals are much lower than the electron temperature, i. e. if the 
particles in the plasma are not in a thermal equilibrium. Numerous plasmas exist far 
from the thermodynamic equilibrium, and are characterized by multiple temperatures, 
related to different plasma particles and diverse degrees of freedom. It is the electron 
temperature Te that often significantly exceeds the temperature of heavy particles T0 
(Te ˃˃ T0). Ionization and chemical processes in such nonequilibrium plasmas are 
mainly determined by the electron distribution function, therefore are not sensitive to 
thermal processes and temperature of the gas. Plasma in a nonequilibrium state is 
usually called nonthermal plasma. An example of nonthermal plasma in nature is the 
aurora borealis.  
In many nonthermal plasma systems, electron temperature is in order of several eV 
(1 eV approximately equals to 11,600 K), whereas the temperature of neutrals and 
ions is close to room temperature. Nonthermal plasmas are usually generated either 
at low pressures or at lower power levels compared to thermal plasmas, or in 
different kinds of pulsed discharge systems.  
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Emission of light and heating are by-products of the plasma generation process. 
The rates of such processes strongly depend on power input and the used gas 
composition and can often be far from the equilibrium distribution. Chemically active 
plasmas exhibit multi-component systems that are highly reactive due to large 
concentrations of charged particles (electrons, negative and positive ions), excited 
atoms and molecules, reactive species, and UV photons. 
Ions are heavy particles, so usually they cannot receive high energy directly from 
electric fields due to intensive collisional energy exchange with other plasma 
components. These collisions with plasma components are the principal process for 
the formation of reactive species. [18] 
There are different ways to create cold plasma at atmospheric pressure. Plasma 
ignition can be pulsed. This means that the ambient air is only partially ionized and 
electrons are energized whereas at the same time the ion temperature remains at 
room temperature. Another possibility of reducing the temperature of the plasma 
system (but not of the electrons) would be to dilute the “hot” plasma components by 
inducing a gas flow. 
In general CAPs can be classified into three types: direct plasmas, indirect plasmas 
and “hybrid” plasmas (Table 1). 
  
Introduction 
16 
 
Table 1: Characteristics of different CAP technologies. [12] 
 Direct plasmas Indirect plasmas “Hybrid” plasmas 
plasma 
sources / 
examples 
Floating electrode 
dielectric barrier 
discharge (FE-DBD) 
Plasma jet, plasma 
plume, plasma 
bullets, plasma torch 
(e.g. MicroPlaSter), 
plasma gun 
Surface-Micro 
Discharge (SMD) 
gas air noble gas / air air 
Current 
through the 
treated sample 
high low low 
UV radiation relatively weak relatively strong relatively low 
Reactive 
species 
are produced in the 
plasma 
are produced by 
mixing plasma and 
air 
are produced in the 
plasma 
plasma species 
which reach 
the treated 
sample 
Reactive species and 
positive/negative ions 
Mainly reactive 
species 
Mainly reactive species 
and a small amount of 
positive/negative ions 
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Table 2 gives a small overview of research groups, which are working with cold 
atmosphere pressure plasma, including the main technology they use.  
Table 2: Examples of groups all over the world which are working with different cold 
atmospheric plasma sources. The table raises no claim to completeness. 
Group Technology 
Drexel University, Philadelphia, USA FE-DBD [21] 
Gamaleya Research Institute, Moscow, 
Russia 
MicroPlaSter ß, argon flow [22] 
George Washington University,  
Washington D.C., USA 
Plasma jet, helium flow [23] 
GREMI, University of Orlèans, France DBD in air [24] 
HuaZhong University, China DBD plasma plum, helium flow [25] 
INP Greifswald, ZIKplasmatis, Germany DBD plasma jet (kinPen) [26] 
Loughborough University, Great Britain  Microplasma jet, helium flow [3] 
Max Planck-Institute, Garching, Germany MicroPlaSter ß (argon flow) [13], SMD in 
air [27] 
Old Dominion University, Norfolk, USA plasma pencil, bullets, helium flow [28] 
Pohang University of Science and 
Technology, Republic of Korea 
Pulsed plasma jet [29] 
University of California, Berkeley, USA SMD in air [4] 
University of Eindhoven, Eindhoven, 
Netherlands 
RF-DBD, plasma needle, argon/oxygen 
mix flow [30] 
University of Nagoya, Nagoya, Japan DBD, argon flow [31] 
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Direct plasmas 
Devices with floating electrode dielectric barrier discharges (FE-DBDs) work with 
the (biological) sample as a counter electrode and are therefore called direct 
plasmas. FE-DBDs produce the plasma in the gap between the living tissue and the 
insulated electrode of the device thereby generating high concentrations of plasma 
species (Figure 2).  
 
Figure 2: Floating Electrode Dielectric Barrier Discharge (FE-DBD) device. The plasma is 
produced between the insulated electrode of the device and the treatment target (finger) – the 
floating electrode. The picture was taken from Fridman et al. [18] 
Indirect plasmas 
A very popular way to create cold plasma is called indirect. Here plasma is 
produced between two electrodes and then transported to the sample via a gas flow. 
The transport of the charge carriers (and the produced molecules) away from this 
discharge region results from the gas flow and diffusion. Most current CAP plasmas 
are generated in helium or argon mixed with a small amount of reactive gases such 
as oxygen; however, they can also be generated in molecular gases such as air. [32, 
33] As air is mainly composed of nitrogen (approx. 78%) and oxygen (approx. 21%) 
the generation of cold atmosphere pressure plasma in air mainly results in formation 
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of reactive nitrogen and oxygen species. [34-37] Several indirect plasmas have been 
developed - one example is the so called plasma jet. [38-42] 
 
Figure 3: Different representatives of indirect plasma sources- plasma jets [41, 43] and the 
plasma torch (MicroPlaSter ß).  
“Hybrid” plasmas 
So called “Hybrid” plasmas represent a combination of direct and indirect plasmas. 
The plasma is created by electrodes and the produced species are transported 
mainly via diffusion onto objects. There is no external gas flow applied. This 
technique is the basis for the so called Surface Micro - Discharge (SMD) technology 
and is described in detail in the next chapter as it is the basic technology of all 
devices that were used in this study.  
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3.3 SMD Device 
The Surface Micro - Discharge (SMD) technology formed the foundation to build 
low- price, robust and scalable plasma electrodes. [44] The SMD devices used in this 
study are producing cold, non-thermal plasma at atmospheric pressure by short 
intervals (in the range of 100 ns) of plasma ignition resulting in only partial ionization 
of the ambient air. Thereby, electrons are energized and reach temperatures of a few 
eV while simultaneously the ion temperature remains at room temperature. The 
overall temperature of the system does not exceed room temperature since the 
ionization degree is low - at its maximum 10-7.  
The basic principle of such a SMD electrode is shown in Figure 4. The SMD 
electrode is composed of a sheet electrode, an insulator and a grounded mesh grid 
which are mechanically pressed together. By applying high voltage across the 
dielectric in the range of kV at frequencies in the range of kHz the structured (mesh 
grid) electrode creates local “hotspots” in electric field strength, which enables the 
formation of the microdischarges. 
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Figure 4: Basic principle of the Surface Micro - Discharge (SMD) technology. [20] On the 
surface of the mesh grid many (Micro)discharges produce a small layer of plasma. 
Based on the SMD technology a device was established to fit conditions in a 
biological laboratory, the so called FlatPlaSter 2.0. For clinical applications and 
domestic use, this technology was also built into a small handheld device with higher 
power consumption, called MiniFlatPlaSter. To be able to apply different power 
modes on the same electrode a mode transition electrode was finally developed.  
Depending on the power input the proportion of the individual species and 
components varies, but the principal composition is the same for all three devices: 
reactive oxygen and nitrogen species; electrons; charged particles; UV light; heat. 
In a closed volume the temperature during plasma application increases 0.2°C/min. 
This has neither for prokaryotes nor for eukaryotes a remarkable effect.  
Main UV components emitted by the devices are in the wavelength range between 
280 and 400 nm and correspond to the N2 second positive system (Figure 5). 
Furthermore, insignificant intensities of UVC light emission can be detected. The UV 
power density was measured to be 25 nW/ cm2. Altogether this UV light emission has 
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no biological effect and therefore doesn’t need not to be taken into account for this 
study.  
 
Figure 5: Optical emission spectroscopy in the low power mode in air. No emission of UVC 
light, only low dose emission of UVB and UVA light could be detected (manuscript in 
preparation by Shimizu et al.). 
The micro-discharges of the electrode have an extent of typically 2 mm and tend to 
align along the dielectric surface. Hence the plasma forms a very thin layer of less 
than one mm thickness. Therefore only a small fraction of the plasma itself (electrons 
and ions) and the short-lived species may reach the treatment sample, which is 
typically placed a few mm to cm away from the electrode. Simulations using 
computational modelling contained more than 600 chemical reactions for the analysis 
of the plasma discharge. But mainly long-lived components such as O3, NO2, N2O, 
N2O5, HNO2, HNO3, H2O2, etc. reach the treatment area via diffusion and/or 
convection.  
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The major reaction pathways in the region under the discharge layer are those with 
ozone. Figure 6 shows that the measured ozone density varies in SMD plasmas for 
different power input. For low power input (black curves with power consumptions 
ranging from 9.5·10-4 W/cm2 to 0.10 W/cm2) the ozone concentration increases 
monotonically (in some cases even up to several 1000 ppm) and finally saturates.  
a) b) 
  
Figure 6: Time dependent ozone production of the SMD device in air.  
a) Time evolution of the ozone density (𝒏𝑶𝟑) produced by the SMD electrode (in a confined 
volume of 5 cm3) for different power consumptions measured with UV absorption 
spectroscopy at 254 nm. The power consumption of the FlatPlaSter 2.0 is approximately 
0.02 mW/cm². 
b) Time evolution of the ozone density with power consumptions of 0.56 W/cm2 and higher. The 
applied voltage was 15 kVpp. The power consumption of the MiniFlatPlaSter is approximately 
0.5 W/cm². [35] 
For higher power input (green and red curves with power consumptions ranging from 
0.25 W/cm2 to 2.6 W/cm2) the ozone concentration first increases, but afterwards 
decreases again immediately. Model calculations suggest that the ozone depletion at 
higher power densities is caused by quenching reactions with nitrogen oxides that 
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are in turn created by vibrationally excited nitrogen molecules which react with 
O atoms: 
𝑁2 + 𝑂2 ⇌ 2 𝑁𝑂 
2 𝑁𝑂 + 𝑂2  ⇌ 2 𝑁𝑂2 
𝑂3 + 𝑁𝑂 → 𝑁𝑂2 + 𝑂2 
𝑂3 + 𝑁𝑂2 → 𝑁𝑂3 + 𝑂2 
It is well known that the ozone emission from the plasma discharge is a key 
problem for in vivo applications if atmospheric plasmas in ambient air are used. The 
Immediately Dangerous To Life or Health Concentrations (IDLHs) given by the US 
National Institute for Occupational Safety and Health (NIOSH) for ozone is 0.1 ppm 
for 8 hours continuous exposure per day (for 6 days a week) (www.cdc.gov/niosh). 
But as described above when plasma is ignited in a closed volume ozone will be 
quenched and converted into nitrogen oxides. For NO, the IDLH is 100 ppm and 1 
ppm for NO2.  
As the current SMD devices mainly use the surrounding air for plasma production, 
the produced plasma chemistry will change if the humidity or ambient temperature 
varies. Humidity ranges from 20-80% and temperature ranges from 15-35°C do not 
affect the bactericidal properties of CAP, [45] but changing conditions may have an 
influence on CAP effects on eukaryotic cells and tissue and therefore needs to be 
controlled carefully. Alteration of the power input leads to a change from a mainly 
ozone based regime (low power mode) to a nitrogen based regime (high power 
mode). In a collaboration with the Chemical and Biomolecular Engineering Faculty at 
the University of Berkeley this ‘mode transition’ was confirmed by Fourier transform 
Introduction 
25 
 
infrared spectroscopy (FTIR) measurements carried out with a SMD electrode with a 
power input of 0.3 W/cm2 (Figure 7 a). In addition species such as N2O, NO2 and 
HNO3 were identified. Interestingly these measurements also revealed that the 
experiment itself can influence the produced plasma chemistry of the SMD electrode 
showing that if a thin liquid film is present, e.g. if cells covered with medium are 
treated with CAP, a reduced decline rate of O3 can be found (Figure 7 b).  
a) b) 
  
Figure 7:  
a.) IR absorption spectrum of the plasma gas (power consumption 0.3 W/cm2) in the absence of 
H2O.  
b.) IR absorption spectrum of the plasma gas (power consumption 0.3 W/cm2) in the presence 
of a H2O layer. 
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3.4 Chemistry in liquids 
Plasma is produced on a mesh grid some millimetre above the sample. The 
biological sample is either in solution or dry, only covered by a thin layer of liquid. All 
components in the plasma diffuse through a so called “afterglow region” between the 
electrode and the sample and are then dissolved by the liquid (Figure 8).  
 
Figure 8: Schematic drawing of species in air and in liquid. 
As mentioned before, only long living species such O3, NO2, N2O, N2O5, HNO2, 
HNO3, H2O2 reach the sample, in which O3 and NO2 are quantitatively the most 
important. [36] 
As the sample is covered by a thin layer of liquid, reactive species then dissolve 
into the liquid. This process underlies the law of Henry: 
𝑘𝐻 =
𝑐𝐻
𝑝𝐻
 
where c is the concentration (or molarity) of gas in solution (in mol/L), p is the partial 
pressure of the gaseous solute H above the solution (in bar) and kH is a constant with 
the dimensions of pressure divided by concentration. The constant kH, known as the 
Henry's law constant, depends on the solute, the solvent and the temperature.  
Introduction 
27 
 
Table 3 gives the Henry’s law constants for the important species of plasma which 
reach the sample. 
Table 3: Henry’s law constants of important reactive species involved in the plasma chemistry. 
[National Institute of standards and technology] 
species Henry’s constant [
𝒎𝒎𝒎
𝑳∙𝒃𝒃𝒃
] 
O3 0.011 
NO2 0.012 
N2O 0.025 
N2O4 1.6 
H2O2 82000 
 
As an example, the calculation for ozone in the setup for the FlatPlaSter 2.0 with 
cells (Figure 10) is shown. As the plasma devices are working in ambient air, we use 
the ambient pressure for our calculations. We calculate with a minimal height of the 
liquid of 1 µm (cell culture dish r = 5 cm) as the medium is sucked off the sample 
before the plasma treatment. The distance between the electrode and the sample is 
18 mm and the volume is closed. Therefore we have an air volume of 0.000142 m³. 
From the measurements of the ozone evolution we know, that after 1 minute CAP 
application the ozone concentration is 550 ppm, which equals to 550 ml/m³. This 
corresponds to a partial pressure of O3 in air: 
𝑝𝑂3 = 0.56 𝑚𝑚𝑚𝑚. 
With this we can calculate the concentration of ozone in solution: 
𝑐𝑂3 = 𝑘𝑂3 ∙ 𝑝𝑂3 = 0.0011 
𝑚𝑚𝑚
𝐿 ∙ 𝑚𝑚𝑚
∙ 0.00056 𝑚𝑚𝑚 
𝑐𝑂3 = 62 µ𝑀. 
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In our setup with a liquid volume of 8 µl this results in 0.0005 µmol solved ozone 
(corresponding 0.024 µg).  
In aqueous solutions ozone decomposes mainly to O2, HO2 and OH. The dissolved 
ozone initiates a reaction with the hydroxyl radical (OH‐), resulting in the production 
of HO2 and the superoxide radical (O2−). [46] 
𝑂3− + 𝐻2𝑂 → 𝑂𝐻 + 𝑂2 + 𝑂𝐻− 
𝑂3− + 𝑂𝐻 → 𝑂2− + 𝐻𝑂2 
𝑂3 + 𝑂𝐻− → 𝐻𝑂2− + 𝑂2 
Furthermore, O2- is converted to the hydroxyl radical (OH‐) and nitrogen dioxide 
(NO2) in the presence of the nitrosyl cation (NO+). [47-51] 
𝑂2− + 𝑁𝑂+ + 𝐻2𝑂 → 2𝑂𝐻− + 𝑁𝑂2 
𝑁𝑂+ + 𝐻2𝑂 → 𝐻𝑁𝑂2 + 𝐻+ 
4𝑁𝑂2⋅ + 𝑂2 + 2𝐻2𝑂 ⇌ 4𝐻𝑁𝑂3 ⇌ 4𝑂𝑁𝑂𝑂𝐻 
Pavlovich and colleagues measured the key chemical species in CAP treated 
aqueous buffer (PBS) using a SMD device similar to the FlatPlaSter 2.0. [52] The 
results revealed that the aqueous chemistry corresponds to the air plasma chemistry 
– i.e. a transition from the ozone mode to the nitrogen mode can be observed as the 
discharge power density increases (Figure 9).  
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a) b) 
  
c) d) 
  
Figure 9: Aqueous chemistry in plasma-treated PBS varying discharge power density:  
(a) hydrogen peroxide and (b) nitrite (black) and nitrate (white)  
Ozone chemistry in plasma-treated PBS:  
(c) varying discharge power density at a fixed exposure time of 300 s and  
(d) varying exposure time at fixed power densities of 0.05 W/cm2 (black) and 0.30 W/cm2 (white) 
The reactions above show us that reactive species not only dissolve in the liquid but 
also react with the liquid and the newly generated species (as seen above) 
themselves interact with the cells. Once the reactive oxygen or nitrogen species 
(RONS) reach the cell, they might activate cell surface receptors and propagate the 
opening of pores and membrane channels. In case RONS gain access to different 
cell compartments, the levels of RONS attained in the cell are crucial for their 
influence on cell fate. At physiological low levels, RONS function as ‘redox 
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messengers’ in cellular signalling and regulation, whereas excess ROS induce 
varying oxidative damage to proteins, lipids and DNA.  
In turn these alterations: 
- inactivate metabolic enzymes, ionic pumps and structural proteins 
- disrupt cell membranes and break nucleic acids, 
resulting in the dysfunction of multiple cellular processes. [53, 54]  
The final concentration of solved ozone in, for example, swimming pools must not 
exceed 0.05 mg/L to prevent any kinds of skin irritation. In our experimental setup the 
portion of solved ozone in the liquid around the sample is therefore negligible. In cell 
culture models 3 % hydrogen peroxide would be lethal for both bacteria and 
fibroblasts. [55] A 3% solution of hydrogen peroxide is widely used as a disinfection 
agent in domestic areas or for contact lenses, as a bleaching agent in dentistry and 
also for hair. Nitric oxide (NO) is an effective inhibitor of lipid peroxidation serving 
membrane function and integrity. [56] Moreover, several lines of evidence indicate 
that in human skin NO is involved in the control of wound-healing processes, allergic 
skin manifestations, microbicidal activity, antigen presentation, proliferation and 
differentiation of epidermal cells, and in the regulation of innate immune reactions as 
well as in inflammatory responses. [57-62]  
Nitric acid is a corrosive and a powerful oxidative agent in contact with skin. 
Systemic effects are unlikely, however, and the substance is not considered a 
carcinogen or mutagen. The lethal dose for humans is 430 mg/kg (oral) and 
inhalation should not exceed 2.6 mg/m3 for 15 minutes [datasheet HNO3 Merck]. 
Nitrite is present in blood as a stable oxidation product of NO synthesis or resulting 
Introduction 
31 
 
from an intake of nitrite-containing food; as a constituent of sweat, nitrite is found at 
concentrations up to 15 μM and is assumed to be formed on the skin surface by 
commensal bacteria. Moreover, nitrite is used medically as broncho- and vasodilating 
agent and as an antidote against cyanide poisoning. [62-65]  
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3.5 Plasma devices used in this study 
FlatPlaSter 2.0 
The SMD technology is the fundamental principle of all devices that were used in this 
study. The FlatPlaSter 2.0 incorporates the SMD electrode (size 9 x 13 cm2) into a 
box made out of Teflon and Polyoxymethylene as shown in Figure 10: 
 
Figure 10: CAP device (FlatPlaSter 2.0), based on the SMD technology. The samples to treat 
were placed directly beneath the electrode. The position of the electrode is adjustable and was 
kept at 1 mm above the plate. The door of the device was closed during the CAP treatment, so 
that the species produced by the plasma were confined inside. [66] 
The SMD electrode itself consists of a 0.5 mm thick Teflon plate which is 
sandwiched by a brass planar plate and a stainless steel mesh grid (line width 2 mm, 
opening 10 mm, height 1.5 mm). High sinusoidal voltage of 9 kVpp with 1 kHz in 
frequency is applied between the brass electrode and the mesh electrode. The 
plasma is produced in many nano- and microdischarges, aided by the strong electric 
field produced around the wires of the mesh electrode by the potential difference with 
respect to the other (sheet) electrode. The power consumption for the plasma 
discharge is 0.02 W/cm2 and was measured with the Lissajous method using a 1 μF 
capacitance. [67] Figure 11 shows the ozone evolution of this device. 
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Figure 11: Ozone evolution of the plasma produced by the FlatPlaSter 2.0. The concentration 
increases monotonically and evens out at a level of approximately 550 ppm. 
For the CAP treatment itself with the FlatPlaSter 2.0, the treatment sample is 
placed inside the box beneath the SMD electrode. A door - installed on one side of 
the box - further ensures that the produced plasma species do not escape and are 
confined inside. Transportation of these plasma species to the treatment sample is 
realized via diffusion - i.e. no additional gas flow is introduced. The distance between 
the SMD electrode and the treatment sample is variable and can be adjusted. The 
FlatPlaSter 2.0 was used for the treatment of bacteria in solution [66] and for 
treatment of primary human dermal fibroblasts. 
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a) b) 
  
Figure 12: Schematic drawing of the front side of the FlatPlaSter 2.0. Experimental setup for  
a) bacteria treatment in solution [66] and  
b) treatment of primary human dermal fibroblasts. 
MiniFlatPlaSter 
Besides the FlatPlaSter 2.0, different handheld devices were developed and 
examined (Figure 13). The handheld battery-operated plasma device incorporates an 
electrode possessing the Surface Micro - Discharge (SMD) Technology [20] and 
uses the surrounding air for plasma production. The device itself is designed for 
portable usage and therefore incorporates the high voltage power supply for plasma 
generation inside. The HV power supply provides a pulsed waveform voltage signal 
between -2 kV and +5 kV and a repetition rate of approximately 6.75 kHz. [68] The 
roundly shaped electrode with a diameter of 2.8 cm - located at the top of the device 
- consists of a glass Epoxy board, which is sandwiched by a copper foil layer and a 
stainless steel mesh grid. By applying the high voltage signal between the copper 
plate and the stainless steel mesh, many micro-discharges - and therefore plasma - 
are produced on the stainless steel mesh. [69] Figure 14 shows the ozone evolution 
of the plasma produced by the MiniFlatPlaSter. The ozone concentration first 
increases, but after 10 seconds decreases again immediately. 
  
Introduction 
35 
 
a) b) 
 
 
c) 
 
Figure 13:  
a) Schematic picture of the CAP device that operates according to Surface Micro - Discharge 
(SMD) technology and uses the surrounding air for plasma production. It consists of the 
following five parts: (1): cylindrical tube for housing the plasma generation units, (2): Kapton 
insulation layer which covers the copper foil layer (3) laminated on the backside of the Epoxy 
dielectric board (4), (5): mesh electrode made out of a stainless steel grid. By applying high 
voltage (HV) between the copper plate (3) and the mesh grid (5) the plasma is produced by 
micro discharges on the side of the mesh grid (5).  
b) Image of the electrode. 
c) Experimental setup with a 6 well plate. [69] 
 
Figure 14: Ozone evolution of the plasma produced by the MiniFlatPlaSter. The ozone 
concentration first increases, but decreases after 10 seconds again immediately.   
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Mode transition electrode 
The electrode consists of a 0.5 mm thick Al2O3 plate sandwiched by a copper high 
voltage electrode and a wire mesh (separation 5 mm) which is electrically grounded.  
a) b) 
 
 
Figure 15:  
a) Image of the discharge of the mode transition electrode.  
b) Evolutions of ozone concentrations using the mode transition electrode. 
The applied voltage was 9.5 kVpp with sinusoidal waveform using a function 
generator and a high voltage amplifier (Trek Inc. model 10/10B). In order to change 
the plasma products (chemistry) [35], the frequency of the applied voltage was 
changed from 60 Hz to 2 kHz. The plasma was produced on the mesh electrode 
(Figure 15:). From the SMD plasma, the UV power onto the objects is negligibly small 
in general. Using this electrode, the maximum UV power was 50-80 nW/cm2 
measured by HAMAMATSU UV power meter. This UV power is not high enough to 
give a bactericidal property using our treatment time on bacteria. Figure 15 shows 
typical evolutions of ozone concentrations using the mode transition electrode.  
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3.6 Nosocomial infections and antibiotic resistance 
Staphylococcus aureus is a Gram-positive bacterium which colonizes the skin and 
is present in the anterior nares in about 25–30% of healthy people. [70] Among 
Staphylococcus aureus isolates, Methicillin resistant Staphylococcus aureus (MRSA) 
are one of the most important causative agents in healthcare-associated infections all 
over Europe. [71] S. aureus is the primary cause of lower respiratory tract infections 
and surgical site infections and the second leading cause of nosocomial 
bacteraemia, pneumonia, and cardiovascular infections. [72, 73] Infections with 
S. aureus are especially difficult to treat because of evolved resistance to 
antimicrobial drugs. Resistance to Penicillin and newer narrow-spectrum β-
lactamase–resistant Penicillin antimicrobial drugs (e.g. Methicillin, Oxacillin) 
appeared soon after they were introduced into clinical practice in the 1940s and 
1960s, respectively. [74] Penicillin resistance was initially confined to a small number 
of hospitalized patients, but resistance spread as the use of penicillin increased, first 
to other hospitals and then into the communities. [75] The World Health Organization 
(WHO) considered the resistance of bacteria against antibiotics as one of the 
greatest threats to human health in 2009. In 2014 they released a first global report 
on antibiotic resistance. The report reveals high levels of resistance to third 
generation Cephalosporins in K. pneumoniae throughout the European Region. In 
some settings, as many as 60% of S. aureus infections are reported to be Methicillin 
resistant (MRSA). A high percentage of hospital-acquired infections are caused by 
MRSA or multidrug resistant Gram-negative bacteria. The high proportions of 
antibiotic resistance in bacteria that cause common infections (e.g. urinary tract 
Introduction 
38 
 
infections, pneumonia, bloodstream infections) in all regions of the world should be 
an alarming signal to man. The report finds that although most countries in the EU 
have well-established national and international systems for tracking antibiotic 
resistance, countries in other parts of the Region urgently need to strengthen or 
establish such systems. [76] 
In 2007, 10 out of 28 countries, mainly southern European countries, the UK and 
Ireland (high endemic countries), reported MRSA proportions of 25 % or higher. In 
the northern part of Europe, in particular the low endemic countries (Norway, 
Sweden, Finland, Denmark, Iceland and the Netherlands) the proportion of isolates 
resistant to methicillin remained below 2%. [10] In addition to that, the ESGNI-005 
Study on intravascular catheter-related infections reported that S. aureus was 
isolated more frequently from samples of hospitals in non-EU countries. 40% of all 
isolates were resistant to Oxacillin, as were 63.4% of coagulase-negative 
Staphylococcus spp. isolates. [77] Data from the National Nosocomial Infections 
Surveillance System (USA) suggest that in intensive care units the proportion of 
S. aureus isolates that are resistant to methicillin has increased to 59.5%–64.4%. 
[78, 79] Recent reports also suggest that community-associated MRSA infections 
have become the dominant cause of community-associated S. aureus skin and soft 
tissue infections [80, 81]. This fatal trend of increasing resistances faces another 
inexorable trend - the lack of new antibiotic drugs. [82, 83]  
And as if this is not bad enough, there are many bacteria related diseases that are 
not curable by antibiotics at all. One alarming example here was the 2011 Hemolytic-
uremic syndrome (HUS) epidemic in Germany. Enterohemorrhagic E. coli (EHEC) 
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are Gram-negative and therefore possess innately resistance against a lot of 
antibiotics. Combatting this pathogen with antibiotics has no clear clinical benefit as 
the secretion of the bacterium is thus prolonged or the course of disease is 
deteriorated by the increased toxin level.  
Already in 1945 Alexander Fleming warned when he obtained the Nobel Prize in 
medicine for the discovery of Penicillin that bacteria can become resistant against 
antibiotics. Decades of uncontrolled usage and a flood of antibiotic prescription - 
especially in non-bacteria related diseases - led to a continuous increase in the 
emergence of highly resistant bacteria. [84-87] Other reasons for the development of 
resistances are: the prescription of the wrong type and insufficient doses of the 
antibiotic for the underlying bacterial infection, the use of a suboptimal antibiotic 
concentration or an inappropriate short or too long duration of antibiotics. [86]  
The “golden ages” of antibiotics are over now and only few pharmaceutical 
companies are engaged in the development of new antibiotic substances. The 
reasons are again obvious – it is not a good business model: the approval for drugs 
for medical use is risky and expensive, the development of resistance to the 
upcoming drug is inevitable, the time frame of successful administration in patients is 
therefore getting shorter and shorter and side effects are unavoidable.  
3.7 Disinfection and prevention 
In 2011 the World Health Day was dedicated to "Combating Antibiotic Resistance" 
due to the aforementioned reasons. It is clear, that we need new approaches to 
target these problems so that we do not end up in an era of incurable bacterial 
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diseases. [88] The first step in this fight is to avoid the spread of pathogens so that 
nosocomial infections and diseases related to that do not occur in the first place. The 
most effective method of containment is disinfection of instruments and especially 
hospital staff and visitors. In hospitals, hand washing practices, which have been 
shown to be the leading intervention for limiting the spread of nosocomial infections, 
should be improved to meet recommended guidelines [89] as well as disinfection of 
instruments and surfaces. There are about 21 million surgical interventions annually, 
worldwide. The surgeons’ disinfection procedure— hand rubbing (3 min) or hand 
scrubbing (5 min)—has to be repeated many times a day, with a number of negative 
side effects arising from the mechanical irritation, chemical and, possibly, allergic 
stress for the skin ([90] and Table 4), not to mention the time required. [20] Table 4 
gives a short summary where disinfection is needed and what the standard 
procedure and agents are at the moment. What they all have in common is that a 
whole bundle of disadvantages and problems remain. 
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Table 4: List of disinfection agents and procedures according to the approval list of the Robert 
Koch-Institute[91] 
Purpose Agent/Procedure Advantages Disadvantages 
Hands/ skin 
wound 
surface 
• alcohols 
• isopropyl alcohol 
• halogens 
• povidone-iodine 
• octenidine 
• polihexanide 
• chlorhexidine 
• silver sulfadiazine 
• potassium 
permanganate 
with additives 
• cheap 
• established 
• absorption time 
• irritation of skin, eyes 
and respiratory tract 
• allergies 
• skin diseases 
• removal of skin grease 
• waste 
surgical 
instruments 
• ultrasound bathes 
• liquid agents like 
aldehydes, phenol 
derivatives, quaternary 
ammonium derivatives 
and oxidative agents, 
e.g. H2O2 
• decontamination 
facilities (thermal) 
• cheap 
• established 
• irritation of skin, eyes 
and respiratory tract 
• allergies 
• skin diseases 
• danger of fire and 
explosion 
• risk of infections 
• risk of burning 
• not for thermo labile 
materials and 
instruments that are 
difficult to access 
• waste 
surfaces • aldehydes 
• phenol derivatives 
• quaternary ammonium 
derivatives 
• cheap 
• established 
• irritation of skin, eyes 
and respiratory tract 
• allergies 
• skin diseases 
• waste 
 
room/air vaporization of 
• formaldehyde 
• H2O2 
• cheap 
• established 
• irritation of skin, eyes 
and respiratory tract 
• allergies 
• skin diseases 
• danger of fire and 
explosion 
• waste 
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3.8 Objective 
The effects of CAP on prokaryotes and eukaryotes were under intensive 
investigation for the last 20 years. Intensive testing all over the world showed that 
bacteria of all kinds – including MRSA and EHEC-viruses, fungi and spores can be 
efficiently inactivated by CAP within a short timeframe, [6, 7, 27, 66, 92-96] thereby 
opening up a new research field called “plasma medicine”. 
Sterilizing temperature sensitive surfaces and medical equipment was the first 
planned application field of CAP. Due to a close cooperation with dermatologists the 
treatment of infected and/or chronic wounds and human skin seemed to be a 
possible area where CAP could be applied.  
There are critical numbers of bacteria above which tissue responds with infection. 
This balance of 105 or fewer bacteria/g tissue is also required for wound healing to 
proceed normally. [97] High levels of bacteria not only result in infection but also 
inhibit normal wound healing. [98] As plasma has proven its bactericidal efficacy 
patients should benefit from a CAP treatment by reduction of the bacterial load in 
open wounds. Chronic wounds in older patients are a big threat and represent a 
large cohort of patients. Resistant bacteria and decreased healing ability are the 
main obstacles to overcome here. But before clinical trials could be carried out, 
experiments had to be done in vitro. In this work parts of necessary in vitro studies 
were carried out. 
The first part deals with the inactivation of bacteria in solution and the impact of the 
different components to the bactericidal effect of CAP. Afterwards, the HPRT assay 
was performed in order to exclude a possible mutagenic potential of CAP. 
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The last part of the present investigation deals with the effect on skin cells in a 
wound. Here a primary culture of human dermal fibroblasts was established in order 
to simulate conditions as realistic as possible. 
Finally it was possible to find a “therapeutic window”: the optimal time, which is 
required to inactivate bacteria and where normal human dermal cells are not yet 
harmed.  
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4. Materials and Methods 
4.1 Technical devices 
Device Model Manufacturer 
Centrifuges 5471R 
4K15 
Eppendorf AG, Hamburg, 
Germany 
Sigma, Deisenhofen, Germany 
CO2 incubator 
Incubator 
(microbiology) 
HERAcell® Thermo Fisher Scientific Inc, 
Waltham, USA 
Flow cytometer FACScalibur ™ Becton Dickinson GmbH, 
Heidelberg, Germany 
Magnetic stirrer RCT basic IKA®-Werke GmbH & Co KG, 
Staufen, Germany 
Microplate reader Asys Expert plus 
Infinite F200 PRO 
Biochrom AG, Berlin, Germany 
Tecan Group Ltd., Männedorf, 
Switzerland 
Microscopes Axiovert 25 
AxioImager Z.1 
Eclipse TS100 
Carl Zeiss AG, Jena, Germany 
Carl Zeiss AG, Jena, Germany 
Nikon, Düsseldorf, Germany 
pH-meter EL-30 Mettler-Toledo GmbH, 
Giessen, Germany 
Spectrophotometer   
Water bath   
 
4.2 Chemicals, reagents and cytostatics 
Substances Abbreviation Manufacturer 
96% Acetic Acid  Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
4,5-Diaminofluorescein DAF-2 Enzo Life Sciences GmbH  Lörrach, 
Germany 
BactoPepton  Invitrogen, Karlsruhe, Germany 
Diamidino-phenylindole DAPI Roche Diagnostics, Mannheim, 
Germany 
Ethyl methanesulfonate EMS Sigma Aldrich, Munich, Germany 
Ethanol  Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
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Formaldehyde  Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Glycerol  Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Hydrochloric acid HCl Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Hydrogen peroxide H2O2 Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Isopropanol  Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Methanol  Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Phosphate buffered 
saline 
PBS PAA, Pasching, Austria 
Propidium iodide  Sigma Aldrich, Munich, Germany 
Select agar  Invitrogen, Karlsruhe, Germany 
Spermine NONOate  Sigma Aldrich, Munich Germany 
Select Yeast Extract  Invitrogen, Karlsruhe, Germany 
Sodium chloride NaCl Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Sodium hydroxide NaOH Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
Tris  Carl Roth GmbH &Co KG, Karlsruhe, 
Germany 
 
4.3 Software 
Software Producer 
Adobe® Acrobat® X Suite Adobe Systems incorporated, San Jose, 
USA 
Axiovision Rel. 4.8 Carl Zeiss Microscopy, LLC, Thornwood, 
USA 
EndNote X7 Thomson ISI Research Soft, NY, USA 
FlowJo analysis software Tree Star Inc., Ashland, USA 
GraphPad Prism® GraphPad Software, LaJolla, USA 
NIS Elements F 3.2 Nikon Instruments Inc., Melville USA 
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4.4 Consumables and additives 
Substance / material Abbreviation Manufacturer 
Antibiotic/Antimycotic A/A Sigma Aldrich, Munich, Germany 
Cell culture inserts for 
migration assays 
 ibidi, Munich, Germany 
Collagenase Type II  life technologies, Darmstadt, 
Germany 
Dissection instruments  Carl Roth GmbH &Co. KG, 
Karlsruhe, Germany 
Dispase II  life technologies, Darmstadt, 
Germany 
Dulbecco’s Modified 
Eagle Medium 
GlutaMAX-I, high 
Glucose 
DMEM life technologies, Darmstadt, 
Germany 
Fetal bovine serum FCS life technologies, Darmstadt, 
Germany 
McCoys 5A medium  life technologies, Darmstadt, 
Germany 
Mitomycin C from S. 
caespitosus 
 Sigma Aldrich, Munich, Germany 
Neubauer 
hemocytometer 
 VWR International GmbH, 
Darmstadt, Germany 
Penicillin/Streptomycin P/S life technologies, Darmstadt, 
Germany 
Petri dishes for 
bacterial culture 
 SARSTEDT AG &Co., 
Nümbrecht, Germany 
Phosphate buffered 
saline 
PBS PAA, Pasching, Austria 
RNase A  Sigma Aldrich, Munich, Germany 
Serological pipettes, 
centrifuge tubes 
 SARSTEDT AG &Co., 
Nümbrecht, Germany 
6-Thioguanine 6-TG Sigma Aldrich, Munich, Germany 
Trypsin  life technologies, Darmstadt, 
Germany 
Tissue culture 
dishes/flasks/test 
plates 
 TPP Techno Plastic Products AG, 
Trasadingen, Switzerland 
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Cell culture media and solutions 
Media Components 
Cell freezing medium DMEM + 20 % FCS + 5 %DMSO 
Medium for V79 DMEM + 10% FCS + 1% P/S 
Medium for primary culture McCoy’s 5 A + 10 % FCS + 1% A/A 
Tissue disaggregation solution Dispase + 1% A/A 
Tris buffered saline 2.42 g Tris, 8 g NaCl, pH 7.6 with acetic 
acid, ad 1000 ml H2O 
 
4.5 Bacterial culture 
ATCC 9637’ Escherichia coli (kindly provided by Dr. Hans-Ulrich Schmidt, 
Department Med. Microbiology and Hospital hygiene, Hospital Munich Schwabing) 
were maintained according to standard protocols. [99, 100] A wire loop was flamed 
and cooled on a spare sterile agar plate. Using the wire loop, an inoculum of bacteria 
was streaked across one corner of a fresh agar plate. The wire loop was flamed and 
cooled again. It was passed through the first streak and then streaked again across a 
fresh corner of the plate and repeated again to form a pattern. The plate was 
incubated upside down at 37°C for 16 h until colonies developed.  Liquid Lysogeny 
Broth Medium (LB Medium) was inoculated with a healthy colony, picked from a 
freshly streaked plate and incubated for 16 hours in the shaking incubator at 37°C 
and 200 rpm. Cultures were stored for 14 days in the refrigerator at 4°C. 
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4.6 Cell cultivation 
Cultivation and cryopreservation of V79 cells 
The standard cell line for the hypoxanthine-guanine phosphoribosyl transferase 
(HPRT) assay is V79 Chinese hamster lung fibroblasts. They were maintained in 
DMEM supplemented with 10 % FCS and 1 % P/S under standard cell culture 
conditions at 37°C and 5 % CO2. Cells were passaged twice a week. Therefore, cells 
were washed with PBS, trypsinized for cell detachment and then seeded in fresh 
medium. 
For cryopreservation, cells were harvested at 70 % confluence and dissolved in 
freezing medium. After gradual freezing for 2 days at -80°C, cells were stored at -
180°C in liquid nitrogen. 
Primary cell culture 
Primary human dermal fibroblasts (PHDF) were isolated from adult donors which 
underwent resection of melanoma. 
Excised specimen were transported in McCoy’s 5a medium supplemented with 
1% A/A, transferred into tissue disaggregation solution and incubated at 4°C over 
night. The dermis was then peeled off the epidermis and cut into small pieces (>0.5 
cm). Tissue pieces were then digested in Trypsin supplemented with Collagenase (2 
mg/ml) for 1 hour at 37 °C. Cells were strained by pipetting and centrifuged 
afterwards at 400 x g for 10 minutes. The supernatant was discarded and the cell 
pellet was obtained in primary culture medium. Cells were seeded and cultured under 
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standard cell culture conditions at 37°C and 5 % CO2. Cells were used until passage 
12 and then discarded. 
In addition to that normal human dermal fibroblasts (NHDF) were purchased from 
Promocell (Heidelberg, Germany) and cultured in McCoy’s (+ 10 % FCS + 1 % A/A) 
under standard cell culture conditions at 37°C and 5 % CO2. NHDF cells were 
passaged and cryopreserved like V79 cells. 
4.7 Treatment of bacteria in solution with the FlatPlaSter 2.0 
Plasma application and experimental setup 
In the setup used in this study, bacteria were treated with the FlatPlaSter 2.0 in 
20 µl of Tris buffered saline (TBS, pH 7.6) in wells of a 96 well plate. The 96 well 
plate was treated with CAP with a distance between the electrode and liquid surface 
of ~ 10 mm. The liquid height in the well was ~ 0.63 mm (Figure 12 a). 
Cellnumber tests 
102 – 108 cells of E.coli in 20 µl TBS were brought into wells of a 96 well plate and 
treated with CAP for 1, 2, 3, 4, 5 and 8 minutes. Afterwards the samples were 
incubated for 1 hour at room temperature, spread on agar plates (in different 
dilutions) and subsequently incubated at 37°C for 18 h, so that the surviving bacteria 
could reproduce and form colonies. Dilutions of untreated bacteria were performed 
as a control for the initial cell number. The killing efficacy was calculated from the 
initial cell number and the total count of colony forming units (CFUs). 
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Detection of reactive oxygen species 
Hydrogen peroxide (H2O2) emergence in solution during CAP application was 
detected with the Amplex® Red Hydrogen Peroxide/Peroxidase Assay (Molecular 
Probes) for several time points. In the presence of peroxidase, the Amplex Red 
reagent reacts with H2O2 in a 1:1 stoichiometry to produce the red-fluorescent 
oxidation product resorufin. Excitation was detected at 550 nm and emission at 
595 nm with a microplate reader (Infinite® 200 Pro, Tecan). The Amplex® Red 
Hydrogen Peroxide/Peroxidase Assay was performed according to the 
manufacturer’s protocol with CAP treated bacteria in TBS and TBS alone. 
Detection of nitrites and nitrates 
The Nitrate/Nitrite Colorimetric Assay (Cayman Chemical Company) is based on 
the reaction of Griess Reagents with nitrates (nitrites are first reduced to nitrates) 
which then forms a deep purple azo compound. The assay was performed according 
to the manufacturer’s protocol with the supernatants of plasma treated E.coli in TBS 
and TBS alone. The absorbance was measured photometrically at 550 nm with a 
microplate reader (Infinite® 200 Pro, Tecan). 
Reference experiments with H2O2 and NO 
Reference experiments with H2O2 (Carl Roth) and a chemical NO donor (DEA 
NONOate, Sigma Aldrich) were performed. TBS containing 104 E.coli cells was 
incubated for one hour with H2O2 and DEA NONOate separately and in combination 
to final concentrations in the range of the measured concentrations after the CAP 
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treatment times of 20 µl TBS containing E.coli. Samples were then spread on agar 
and incubated over night at 37°C. CFUs were counted to control the bacterial 
reduction. 
Fluorescence proof of intracellular NO 
To detect NO in injured bacteria, 5 x 106 bacteria in 20 µl TBS were filled in wells of 
a 96 well plate and treated with CAP for 3 min. After the treatment bacteria were 
stained with DAF-2 (Enzo Life Sciences) at a final concentration of 10 µM for 1 hour 
at 4°C in the dark. Bacteria were fixated on microscope slides and nuclei of bacteria 
were additionally stained with 10 nM 4',6-diamidino-2-phenylindole (DAPI, Molecular 
Probes). As controls, living cells and cells treated with a chemical NO donor (DEA 
NONOate, Sigma Aldrich) were prepared. Samples were visualized on an 
Axioimager fluorescence microscope (Zeiss) equipped with a Zeiss Axiocam camera 
and Zeiss objectives and filters. Light was collected through a 63 x 0.4 NA water 
immersion objective. Fluorescence was excited using a 358 nm band pass filter for 
DAPI and 465 - 495 nm for Triazolofluorescein. Emission was detected by a 440 - 
480 nm band pass filter (DAPI) and a 505 - 550 nm band pass filter 
(Triazolofluorescein). Images were captured from three randomly selected areas for 
ten different sets of experiments and data were analysed using Axiovison 4.8 
software (Zeiss). 
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4.8 Treatment of dermal fibroblasts with FlatPlaSter 2.0 
Cell viability 
For the investigation of cell viability after the treatment with CAP 1 x 105 cells were 
seeded in a 6 well plate and grown over night. Cells were treated with plasma without 
medium covering them (fresh medium was added immediately afterwards). Controls 
were kept without medium for the same duration as CAP treatment. Cells were 
incubated for 48 h at standard cell culture conditions and then washed, trypsinized 
and counted with a hemocytometer.  
Migration 
The scratch assay was performed with primary cells and NHDF cells grown to 
confluence in 6 well plates. To see only migration proliferation was inhibited by 
incubating cells for 3 hours with 2 g/l Mitomycin. Then cells were washed, treated 
with plasma (FlatPlaSter 2.0) and at the end a scratch was set with a 200 µl pipette 
tip. Fresh medium was added cells were then cultivated under normal conditions for 
48 hours. Images were made and gap size was measured at three randomized 
positions after the scratch and after 24 hours and 48 hours of incubation. Control 
cells were not plasma treated.  
Flow cytometry 
Cell cycle analysis was carried out by flow cytometry. Cell nuclei containing 
different amounts of DNA in the cell cycle phases were stained with propidium iodide 
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(PI). The G1 phase is featured by two complete sets of chromosomes (2N). During S 
phase, DNA is synthesized and the DNA amount is intermediate between G1 and 
G2. In G2 phase, doubled DNA content defines a tetraploid stage (4N). Following 
RNA and protein synthesis, G2 phase culminates in mitosis (M phase). Regarding 
DNA amount, G2 and M phase are indistinguishable. Apoptotic cells with fragmented 
DNA appear as subG1 population. 
Cells were seeded in 10 cm tissue culture dishes (5 × 105 cells/ dish), allowed to 
attach overnight, and CAP treated (FlatPlaSter 2.0) for the indicated times. Controls 
were treated equally. For FACS analysis cells were washed twice in phosphate 
buffered saline (PBS) and fixed in ice‐cold 70 % methanol at 4°C for at least 2 h. 
Afterwards cells were washed with PBS and then incubated with 100 µg/ ml of 
RNase A for 20 min at 37°C and stained with PI (50 µg/ ml). Cell cycle distribution 
was analysed using the BD FACS Calibur counting 10,000 events per determination. 
Doublet discrimination and analysis of cell cycle distribution was performed with 
FlowJo analysis software. 
4.9 Mutagenicity of CAP (MiniFlatPlaSter) 
Reference experiments with E.coli 
To evaluate a reasonable duration of CAP-treatments for the mutagenicity tests, 
first of all the reduction rate of ‘wet’ E.coli by the MiniFlatPlaSter was measured. 
E. coli K1 ATCC 10538 were used as a model system. A suspension of E. coli in 
phosphate-buffered saline (PBS) with a density of approximately 2 x 108 cells per ml 
was prepared as a stock bacterial suspension. A volume of 0.3 ml of this stock 
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suspension was then distributed homogeneously to Müller-Hinton agar plates (culture 
area approximately 8.5 cm2) and immediately treated with CAP without drying (agar 
surface was wet). For comparison, the experimental setup for the bacterial tests was 
chosen to be as close as possible to the conditions for the experiments with V79 
cells:  
a. the bacteria on the agar were not dried before the CAP treatment, they were 
treated immediately after distribution, meaning that they were still ‘wet’. 
b. the distance between the electrode and the agar surface was set to 17.5 mm. 
c. the volume between the CAP device and the agar surface was closed by a 
plastic ring adapter which had the same inside diameter of a well in a 6-well 
plate. 
d. the E.coli density on the agar plate was chosen to be approximately 106 
colony-forming units (cfu)/cm2, which means that the target surface on the 
agar plate was covered with bacteria to approximately 10 %, similar as for the 
cell experiments. 
CAP-treatment times of 120, 180 and 240 sec were used. Each CAP-treatment was 
repeated three times and the mean of the standard error was then given for the 
statistical variability. After the CAP-treatment, the agar plates were incubated 
overnight at 37°C. Colony forming units in the CAP-treated area were then counted, 
and the reduction due to the CAP-treatment was then calculated. 
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Hypoxanthine-guanine phosphoribosyl transferase (HPRT) assay with V79 cells 
The protocol for the mutagenicity test was modified according to Davies et al. [101] 
In this setup 105 V79 cells were seeded in wells of a 6-well plate and cultured in 
DMEM supplemented with 10 % FCS and 1 % p/s under standard cell culture 
conditions (37°C and 5 % CO2) for 24 hours. Before the CAP-treatment, the medium 
was removed until no visible liquid was seen. The cells were then treated with the 
MiniFlatPlaSter (see Figure 13) for 30, 60, 2 x 60, 3 x 60 and 4 x 60 seconds or for 
30 seconds every 12 hours (in total five times). Positive controls were prepared by 
treating the cells with 0.3 mg/ml ethylmethane sulfonate (EMS, Sigma Aldrich) in full 
medium for three hours. This concentration was chosen in order to guarantee an 
optimum ratio of cell survival and mutant frequency. [102] Negative controls were 
prepared by removing the medium, but without applying a CAP- or EMS-treatment. 
After treatment the cells were cultured in complete medium for three days. In order to 
observe cell behaviour after the CAP-treatment, microscope images of the cells were 
taken before, immediately after, and 1 hour, 18 hours, 24 hours, 48 hours, and 72 
hours after the 240-sec CAP-treatment. After treatment the cells were cultured in 
complete medium for three days.  
At day 4 the cells were washed, trypsinized and counted with a haemocytometer. 
This cellnumber was also an indicator for cell viability. To assess the plating 
efficiency (PE), 250 cells per 6-cm dish were re-plated and maintained under 
standard cell-culture conditions. After another five days colonies were counted. To 
estimate the mutant frequency (MF), 105 cells per 10 cm dish were re-plated and 
cultured. After five days the medium was supplemented with 5 µg/ml of the selective 
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agent 6-TG (Sigma Aldrich). Mutant colonies were counted after 8-10 days of 
incubation. 
4.10 Investigation of mode transition 
Ozone measurement 
Ozone is one of the important products from the SMD plasmas. Here, by an 
absorption spectroscopy the ozone concentration was measured using UV light at 
254 nm in wavelength from a Hg/Ar lamp. Using the mode transition electrode, a 
quartz glass tube with 30 mm diameter and 20 mm height was placed below the 
electrode. The glass tube was on a ceramic plate. By the electrode, the glass tube 
and the ceramic plate, a closed volume was formed. At a height of 10 mm from the 
ceramic plate, the ozone concentration was measured. Environmental humidity is 
one parameter which can change the plasma chemistry. This ozone measurement 
was carried out under 20-23°C with 40-50 W relative humidity. When cell cultures or 
agar plates were treated by the SMD plasma, an increasing in humidity in the closed 
volume was expected. To simulate the condition, we measured the ozone evolutions 
with different powers and different humidities. “Dry” condition means the plasma 
production using the ambient mentioned above. For “Wet” condition, 50 microliter of 
distilled water was distributed on the ceramic plate. Unfortunately, the humidity inside 
the closed volume could not be measured because the volume was too small using 
our measurement system. 
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Bactericidal effect 
A suspension of E. coli (DSM 1116) in phosphate-buffered saline (PBS) with a 
density of approximately 1 × 108 cells per ml was prepared as a stock bacterial 
suspension. A volume of 100 µl of this stock suspension was then distributed 
homogeneously to Müller-Hinton agar plates and dried for 30 minutes. For the mode 
transition electrode the volume between the CAP device and the agar surface was 
closed by a plastic ring adapter which had almost the same inside diameter and 
height of a well in a 6-well plate. Bacteria samples were then treated for 15, 30, 45 
and 60 seconds with CAP. Colony forming units (CFUs) were counted 24 hours after 
incubation at standard conditions. 
Viability of dermal fibroblasts 
For the investigation of cell viability after the treatment with the mode transition 
electrode experiments were carried out in the same manner as described in 4.8 for 
the FlatPlaSter. The experimental setup is similar to the setup with the 
MiniFlatPlaSter (Figure 13 b). The distance between the electrode and the sample 
surface of interest was 17.5 mm and the treatment volume was closed. 
4.11 Statistical analysis 
All statistical significances were evaluated using one or two factor analysis of 
variance (ANOVA) followed by Bonferroni post-test. Differences were considered 
significant at P< 0.001. Experiments were repeated at least three times if not stated 
otherwise. 
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5. Results 
5.1 Treatment of bacteria in solution with FlatPlaSter 2.0 
Studies with the FlatPlaSter 2.0 and other plasma devices already showed that a lot 
of different pathogens could be inactivated within a short time on agar. As wound 
treatment is one of the intended application fields of CAP, inactivation experiments 
were carried out in a small amount of liquid which should simulate the wet wound 
environment. E.coli were treated with the FlatPlaSter 2.0 for indicated times in 20 µl 
of TBS. The height of the liquid in a well of a 96 well plate was 0.63 mm and the 
distance to the electrode was 10 mm (also see Figure 12 a). 
Cellnumber tests 
The initial cell density of E.coli in the liquid had a strong impact on the inactivation 
efficacy. A time dependence in strong correlation to the cell density was 
demonstrated (Figure 16): up to densities of 105 cells / 20 µl high reduction rates of 
up to 5 log steps were achieved in less than 3 minutes of CAP application. At a 
concentration of 106 cells / 20 µl a 6 log reduction was achieved in less than 6 
minutes. In contrast, for higher cell densities above 107 cells / 20 µl the killing 
efficiency was not time dependent anymore and almost no reduction was measured 
for CAP treatment times of up to 8 minutes. 
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Figure 16: Kinetic inactivation curve of 102 – 108 E.coli cells in 20 µl TBS. The bacteria were 
treated for 1, 2, 3, 4, 5 and 8 minutes with CAP. A 5 log reduction was achieved for 3 minutes of 
CAP application for initial cell densities of 105 per 20 µl or lower. For cell densities of 107 / 20 µl 
and higher almost no reduction was achieved for CAP treatment times of up to 8 minutes. [66] 
Peroxides in liquid 
The emergence of peroxides in 20 µl TBS and TBS containing 106 E.coli after 
different CAP treatment times was assessed (Figure 17). The results clearly show 
that the content of hydrogen peroxide in the treated liquids (TBS with/without E.coli) 
increased with longer CAP application times. However, reference experiments with 
hydrogen peroxide show that the measured hydrogen peroxide concentrations after 
CAP application are not high enough to inactivate microorganisms (Figure 19 a). 
Results 
60 
 
 
Figure 17: Emergence of peroxides in 20 µl TBS and TBS containing 106 E.coli after different 
application times. The peroxide content of TBS and TBS containing E.coli increases 
continuously. In TBS containing E.coli the peroxide level is slightly below the level of TBS 
alone. [66] 
Nitrates and nitrites in liquid 
The total nitrite and nitrate content in 20 µl TBS and TBS containing 106 E.coli for 
different CAP application times was measured (Figure 18). The results show that the 
nitrite and nitrate content of both treated liquids (TBS with/without bacteria) is 
significantly increased after CAP application: for a treatment time of 4 min (where a 
5 log reduction of E.coli was achieved) the concentration reached a value of 950 µM 
and 1420 µM for a treatment time of 8 min. However, reference experiments with NO 
possessing concentrations of up to 1500 µM did not reduce bacteria significantly 
(Figure 19 b and c). 
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Figure 18: Total nitrite and nitrate content in 20 µl TBS and TBS containing 106 E.coli after 
different plasma application times. The Nitrate/Nitrite level is similar for TBS and TBS 
containing E.coli. The curves are a nonlinear fit to the data. Error bars show the standard 
deviation. It appears that the nitrate/nitrite concentration may become saturated and there is no 
reduction when the medium contains E.coli – this is in contrast to the Hydrogen Peroxide 
concentration shown in Figure 17. [66] 
Combination of H2O2 and NO 
Reference experiments with a combined application of NO and hydrogen peroxide 
show a much higher inactivation effect on E.coli than a treatment with NO or H2O2 
alone. The concentrations of nitrates and H2O2 that were measured after CAP 
application had no bactericidal effect in the reference experiments with the chemical 
NO donor NONOate and H2O2 (Figure 19 a). But a reduction of 4 log steps can be 
achieved with 1 mM of NONOate in combination with 1.5 mM of H2O2 (Figure 19 b).  
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a) b) 
  
c) d) 
 
 
Figure 19: Reference experiments with a) H2O2 alone, b) NONOate alone and c) combination of 
H2O2 and NONOate. The concentrations in c) correspond to those obtained after 1, 2, 3, 4, 5, 6 
and 8 minutes of plasma application. d) Reference experiments with explicitly higher 
concentrations of NONOate and H2O2. [66] 
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Direct evidence of intracellular NO in E.coli 
 
Figure 20: Living E.coli cells (E.coli live), E.coli cells treated with a chemical NO-donor (E.coli 
NO) and E.coli cells, treated with plasma for 3 minutes (E.coli plasma) 
(a) Channel 1: DAPI staining; (b) Channel 2: DAF-2 staining; (c) Channel 1 + 2 merged.  
Nuclei of all bacteria are stained by DAPI (blue), bacteria that took up NO are stained by DAF-2 
(green). Plasma treated bacteria fluoresce green like those which were treated with a chemical 
NO donor and in contrast to the untreated, living E.coli cells. This means that the plasma 
treated bacteria took up NO during or as a consequence of the plasma treatment. The merged 
image of plasma treated E.coli clearly shows that the uptake of NO is not regularly. The red 
circle shows a bacterium which took up much more NO than those in the yellow circle. [66] 
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A sensitive fluorescent probe (DAF-2) was used to detect NO in cells in real-time 
(Figure 20): controls of living cells show that E.coli cells are not stained by DAF-2 in 
the absence of a NO-donor. CAP treated bacteria clearly possess green 
fluorescence in the same way as bacteria, which were treated with a chemical NO-
donor. As DAF-2 is only converted to DAF-2T in the presence of NO and O2 the 
green fluorescence of CAP treated bacteria is a direct evidence of NO being 
absorbed by cells during or after plasma application. 
Conclusion 
The first step towards wound disinfection is to investigate the different influences of 
CAP on microorganisms. Here it was shown that the initial cellnumber plays an 
important role. The density of cells in the liquid limits the inactivation property at a 
certain point. In combination with the results of the H2O2 and Nitrate/Nitrite 
experiments we assume that there is a time point, where the reactive species, which 
are responsible for the bactericidal action, do no longer diffuse in sufficient 
concentrations into the liquid. 
 
5.2 CAP treatment of dermal fibroblasts with FlatPlaSter 2.0 
As the aim of this part of the study was to test the safety of CAP experiments were 
performed with primary cells that were not immortalized. Fibroblasts from fresh skin 
of 11 adult donors and NHDF cells (Promocell) were cultured and used for 
examinations. Dermal fibroblasts were treated for indicated times with the 
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FlatPlaSter 2.0 without medium covering the cells (for experimental setup see Figure 
12).  
Viability test 
Primary human dermal fibroblasts (PHDF) and NHDF cells were treated with 
plasma and the cellnumber was counted 48 hours afterward. The cellnumber 
decreases with increasing treatment time. Cellnumbers are only significant (P<0.001) 
decreased for treatment times of 60 seconds and longer. 
 
 
Figure 21: Counted cell numbers 48 hours after different CAP treatment times. Cellnumber was 
significant (P<0.001) decreased after CAP treatment times of 60 seconds and longer. 
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Migration 
The migration ability after CAP treatment in fibroblasts was investigated. A scratch 
was originated with a 200 µl pipette tip and proliferation stopped by incubation with 
mitomycin for 3 hours. Cells were then CAP treated and cultured under standard 
conditions for 48 hours. Pictures were taken after 24 and 48 hours. 
The migration of dermal fibroblasts is slowed down with increasing CAP treatment 
time. After 24 hours differences in the recovered gap area can be detected. But after 
48 hours only cells that were treated for 120 seconds were not able to close the gap. 
Strikingly, the gap was even more distinct 24 h and 48 h post-treatment for 
120 seconds possibly due to detachment of cells. 
 
Figure 22: Primary human dermal fibroblasts and NHDF cells were CAP treated and migration 
of the cells was monitored over 48 h. Gap size was initially measured and after 24 h and 48 h.  
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Figure 23: Pictures illustrating the gap directly after the treatment with CAP compared to 
migration in CAP treated and control cells after 24 h and 48 h. 
Cell cycle analysis 
Based on these findings, we assumed that CAP has an influence on the regulation 
of the cell cycle progression. Thus, cell cycle progression of dermal fibroblasts was 
analysed 4 h, 24 h, 48 h and 72 h after CAP exposure. A treatment time of 90 
seconds and higher resulted in a significant arrest in the G2 / M phase of the cell 
cycle 24 hours after CAP application and persisted for at least 72 hours. Here, up to 
a factor two higher amounts of cells in the G2 / M phase was found for the CAP 
treated cells compared to the control cells.  
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a) 
 
b) 
 
Figure 24: CAP treatment induces G2 / M phase cell cycle arrest in dermal fibroblasts after 90 s. 
a) Representative cell cycle distribution of dermal fibroblasts after CAP treatment. Treatment 
was performed only with a thin film of liquid covering the cells. Cell cycle distribution was 
analysed using flow cytometry. 
b) Cells in G2 / M phase [%].The observed arrest in the G2 / M phase is statistical significant 
after 24 hours for 90 s CAP treatment and 120 s and lasts up to 72 hours after CAP treatment. 
P<0.001 
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Conclusion 
After the examination of the bactericidal efficacy of CAP it was necessary to test the 
safety on human skin cells. Results of proliferation, migration and cell cycle analysis 
with primary human dermal fibroblasts showed that there is an effect due to higher 
doses of CAP but that this is not persistent for long time and cells are able to 
rejuvenate.  
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5.3 Mode transition electrode 
Different power modes result in different chemistry regimes – i.e. the produced 
reactive species shift from an ozone- to a nitrogen- based chemistry. To assess the 
impact of these different chemistry modes on as well the bactericidal effect as on the 
safety towards eukaryotic cells i.e. primary fibroblasts, different power modes were 
evaluated by using the mode transition electrode.  
 
Figure 25: Ozone density for mode transition electrode at wet conditions. Until 430 mW/cm2 
input power, the ozone concentration increased monotonically. With 750 mW/cm² input power, 
there is a sudden drop in the ozone concentration after 15 s. 
Figure 25 shows the ozone measurement for the mode transition electrode with a 
small amount of humidity (see 4.10). Until an input power of 430 mW/cm², the ozone 
concentration increases monotonically. At 750 mW/cm², there is a sudden drop after 
15 seconds. 
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Bactericidal effect 
The data (Figure 26) show that a treatment time of 30 s leads to a reduction of 5 log 
steps in the target area with power consumptions of 95, 430 and 750 mW/cm². 
15 seconds of CAP application only leads to a 5 log reduction with a power 
consumption of 430 mW/cm². With 30 mW/cm² higher treatment times (at least 45 s) 
were necessary to obtain a countable reduction of CFUs. This reduction ranges 
between 0.5 and 1 log. 
 
Figure 26: Bacterial reduction for different plasma treatment times and power consumptions. 
Applied voltage was always 8.5 kVPP and the following applied frequencies were used to control 
the power input: 60 Hz, 200 Hz, 1 kHz, and 2 kHz. With power consumptions of 95, 430 and 
750 mW/cm² a log 5 reduction could be achieved after 30 s.  
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Our experiments also show that oxidative stress evoked by ozone leads to bacterial 
inactivation (Figure 27) and that the ozone dose correlates with the log reduction of 
E.coli. Higher ozone density results in higher bacterial reduction. 
 
Figure 27: Ozone dose plotted against log reduction of bacteria. The ozone concentration 
produced by the mode transition electrode [ppm∙s] at different power inputs correlates with the 
log reduction of E.coli. Higher ozone density results in higher bacterial reduction.  
 
Viability of primary human dermal fibroblasts 
As described above by applying different frequencies the amount of ozone that can 
be detected inside the closed volume varies. Aim of this viability test was to 
determine the impact of different concentrations of ozone on primary human dermal 
fibroblasts. 
The results show that there is no big difference in the total cell numbers (Figure 28). 
One can discern a trend in decreasing cellnumbers towards higher treatment times 
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and increasing power consumptions when looking at a close up of the scale (Figure 
28 b). Nevertheless the differences are statistically not significant. 
a) b) 
  
Figure 28: a) Cellnumbers 48 hours after plasma treatment. Cells were treated for 30 s, 60 s, 
90 s and 120 s. Controls were untreated cells. Voltage was always 8.5 kVPP. The cells were 
counted with a Hemocytometer. b) The same graph with a larger scale. 
Figure 29 a shows the correlation between the ozone concentration produced by 
the plasma of the mode transition electrode and the cell viability of primary human 
dermal fibroblasts. In Figure 29 b the “therapeutic window” can be determined as the 
region, where a 5 log reduction of E.coli could be achieved and a cell viability of 75 % 
in dermal fibroblasts could be ensured.  
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a) b) 
  
Figure 29:  
a) Ozone dose plotted versus cell viability. With increasing ozone dose the cell viability of 
dermal fibroblasts decreases. A cell viability of ~75 % depicts an acceptable low proportion of 
harmed cells in agreement with medical doctors. 
b) Cell viability plotted against bacterial log reduction. The “therapeutic window” is marked 
with the magenta circle. Here, there is the best overlap where bacteria are inactivated and cell 
viability is not under 75 %. Error bars are standard deviation. 
The limiting ozone dose here is 2∙104 ppm∙s - the corresponding ozone flux is 
1.4∙1022 O3/cm²:  
𝐷 =  𝑛𝑂3 ⋅ 𝑣 ⋅ 𝑡 = (2 ⋅ 10
−2 ⋅ 2.8 ⋅ 1019)
𝑂3
𝑐𝑚3
⋅ 2.5 ⋅ 104
𝑐𝑚
𝑠
⋅ 𝑠 = 1.4 ⋅ 1022 𝑂3 𝑐𝑚2�  
Conclusion 
Intention of the experiments with the mode transition electrode was to investigate 
the influence of different ozone concentrations on bacteria and on human cells. 
Taken as a whole, ozone is harmful for all kinds of cells. But our experiments 
demonstrate that prokaryotes, at least E.coli, are more disturbed by the higher ozone 
concentration than primary human dermal fibroblasts and that there is a window 
where bacteria are already inactivated and fibroblasts are still healthy.   
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5.4 HPRT assay (MiniFlatPlaSter) 
Another aspect of safety is that no long term effects are caused by the treatment. 
As UV light in the range of 200 - 440 nm is emitted by the SMD devices the 
emergence of mutations has to be ruled out. One standard way of examination is the 
HPRT assay. To simulate a repeated treatment in clinics, not only single treatments 
were performed but also treatments every 12 hours. 
Reference experiments with E.coli 
To evaluate a reasonable duration of CAP-treatments for the mutagenicity tests, the 
reduction rate of ‘wet’ E.coli was measured. The data (Figure 30) show that a 
treatment time of 120 sec leads to a reduction of 5 log steps in the target area. A 
reduction of >106-fold was achieved when the treatment time with CAP was 240 sec. 
For treatment times shorter than 60 sec the number of surviving CFUs in the target 
area was too high for counting. For ‘sufficiently dry’ bacteria on agar (dried for 30 min 
after inoculation), a column ‘30 s dry’ was added to Figure 30: in this case a CAP 
treatment time of 30 seconds led to a reduction of almost 105-fold. 
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Figure 30: Survival of colony forming units (cfu) after different CAP treatment times. The 
control shows the initially plated number of cfu. The data for ‘120 s’, ‘180 s’ and ‘240 s’ were 
obtained by treating the bacteria with CAP on agar, immediately after inoculation (‘wet’). The 
data for ‘30 s dry’ refer to the measurement on a ‘dry’ agar surface – where a drying time of 
30 min was added after inoculation of the bacterial suspension. The error bars correspond to 
the standard deviation. [69] 
Cell viability 
For the HPRT test, the V79 cells were treated with CAP (for experimental setup see 
Figure 13) and afterwards cultured in medium for three days. The number of cells on 
day 4 is presented in Figure 31 and suggests that the number of cells treated for 
240 sec with CAP is in the same range as the number of cells initially seeded (no 
significant difference, P<0.001). Cell numbers for treatment times up to 60 sec 
showed no significant difference compared with the untreated control (P<0.001).  
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Figure 31: Counted cell numbers on day 1 and day 4 after different CAP treatment times, or 
application of EMS. The error bars show the standard deviations. [69] 
Within the used plasma treatment times, both the cell counts and the microscope 
images of the cells (taken after CAP treatment, Figure 32) suggest a decelerated 
proliferation speed rather than apoptosis or necrosis. In microscope images showing 
V79 cells before, immediately after, and 1 hour, 18, 24, 48 and 72 hours after a CAP 
treatment of 240 sec duration, we could not find any evidence for cell death in the 
images (Figure 32). This was taken to support the following hypothesis that the cells 
stopped or slowed down their proliferation due to the CAP treatment. 
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Figure 32: Representative microscope images (10 x magnification) showing V79 cells before, 
immediately after, and 1 hour, 18, 24, 48, 72 hours after the CAP treatment of 240 sec. Although 
the proliferation seems to be decelerated, no apoptotic or necrotic behaviour is visible. [69] 
Mutant frequency 
On day 4 cells were replated (after cell count) and medium was supplemented with 
5 µg/ml of the selective agent 6-TG (Sigma Aldrich). Mutant colonies were counted 
after 8-10 days of incubation. The results of the mutagenicity test are presented in 
Figure 33. CAP treatments of up to 240 sec and repeated CAP treatments of 30 sec 
every 12 hours induced at maximum nine mutants per 105 cells. The control 
treatment with 0.3 mg/ml EMS for three hours induced up to 288 mutants per 
105 cells as expected according to Bradley et al. [102-104] Corresponding to the 
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literature [102-106] and the control (untreated) samples, the mutant frequency 
observed for the CAP-treated samples lies in the range of the naturally occurring 
mutation rate of V79 cells. This means that CAP treatments of up to 240 sec did not 
cause mutations in V79 cells.  
 
Figure 33: Mutant frequency for the negative controls, the EMS treatment and the different CAP 
treatment times. The initially seeded cell number was 105 V79 cells per well. The error bars 
show the standard deviations. [69] 
Conclusion 
The HPRT assay was performed with the MiniFlatPlaSter. But the amount of UV 
light and the range of the emission are comparable for all the SMD devices. The 
results of this study are therefore important for all further studies as it was shown that 
mutations due to CAP do not have to be expected. 
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6. Discussion 
Impact of reactive species on bacterial inactivation by CAP 
The ability to inactivate bacteria with cold atmospheric plasma was demonstrated 
by various groups worldwide and with a wide range of different kinds of pathogens [7, 
27, 30, 92, 93, 107-112] and scrutinized within the first part of this study. 
The inactivation of E.coli with CAP was therefore not new, nevertheless most 
publications and studies regarding this subject dealt with bacteria on agar, which is a 
rather dry surface. Wounds in patients represent a predominantly wet environment 
were bacteria can be hidden in the wound fluid. [113] The aim of the first part of this 
study was thus to investigate whether pathogens in solutions can also be inactivated 
by CAP. As mentioned earlier, the number of pathogens also plays an important role 
for wound healing so the experiments were additionally carried out with different 
initial cellnumbers in the fluid. The results demonstrate that E.coli can be inactivated 
within a short time but that there is a critical number of 107 per 20 µl above which no 
more cells are inactivated. To get a deeper insight in these effects the emergence of 
hydrogen peroxide and nitrites/nitrates into the liquid was measured. While the 
concentration of H2O2 seems to saturate, the amount of nitrites and nitrates 
increases steadily with increasing treatment times. The reference experiments with 
hydrogen peroxide and a chemical NO donor on the other side clearly demonstrate 
that the bactericidal property which was achieved after 3 min of CAP application 
could only be reached with significant higher dosages of H2O2 and NO. 
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Many publications in recent time dealt with “plasma activated water” which means 
that water is treated with CAP and then bacteria are inserted into this. [5, 52, 114] All 
groups could show that by increasing the mixing rate the bactericidal efficacy could 
be significantly increased. Increasing the mixing rate means for example shaking or 
stirring the liquid during CAP application. These results are promising as it shows 
that bacteria could be inactivated in even shorter time than shown in this study and 
consequently shorter treatment times are necessary. 
Safety of CAP in primary culture 
Different types of dermal cells and immune cells - such as keratinocytes and dermal 
fibroblasts - are incorporated in the proceeding of normal wound healing: hemostasis, 
coagulation and inflammation. [113] It begins with inflammation and immune cell 
recruitment to protect tissue from foreign invaders, such as bacteria and viruses. In 
the next phase the skin is resurfaced by stimulating regeneration and repair through 
proliferation of fibroblasts and re-epithelialization of keratinocytes. Wound healing 
plays an important role in protecting the human body from external infections. Cell 
migration and proliferation of dermal fibroblasts – amongst others - are therefore 
essential for proper wound healing. [115, 116] 
As mentioned above, migration and proliferation of fibroblasts are crucial in wound 
healing. Cell lines that are used in cell cultures for all kinds of in vitro examinations 
are normally immortalized to provide easy handling and passaging. Strictly speaking 
this means certain ways of natural cell death were knocked out. In terms of safety of 
a medical device, in our case the SMD device, it is not very meaningful if 
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immortalized cells are not harmed by the treatment. Therefore it was necessary to 
maintain primary cells from fresh human specimen to investigate the behaviour of 
dermal fibroblasts after CAP application. Although an in vitro model always depicts 
an artificial environment, it is indispensable for all kinds of basic research.  
To investigate the influence of CAP on migration and proliferation, primary human 
dermal fibroblasts were treated with CAP for certain times. The cellnumber was 
counted after 48 hours and scratch assays were performed and also observed for 48 
hours. Results of these experiments show a trend towards a decline in cellnumbers 
with increasing treatment time. A deceleration in migration can also be detected with 
higher CAP dosage after 24 hours, but recovers afterwards. 48 hours after CAP 
treatment only cells that were treated for 120 s were not able to close the gap. The 
analysis of the cell cycle distribution supported the suggestion that cells are slowed 
down in proliferation. An arrest in G2 / M phase is visible for cells that were treated 
for 90 seconds and longer. This arrest was prominent 24 hours after CAP treatment 
and sustained for at least 72 hours.  
To implement in vitro studies before bringing new devices to clinical studies is an 
essential prerequisite. Therefore the HPRT (hypoxanthine-guanine phosphoribosyl 
transferase) assay with V79 Chinese Hamster lung fibroblasts was carried out to 
investigate the mutagenic potential of CAP. Not only single treatment times, that 
were far above the intended application time of CAP, but also repeated plasma 
treatments were performed to simulate a clinical application cycle. As the bactericidal 
effect is already at its maximum after 30 seconds on agar and after 3 min in solution, 
the chosen treatment times of 240 seconds and 30 seconds every 12 hours 
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represent an adequate model for this. V 79 cells are the standard cell line to perform 
the HPRT assay as mutations can be induced easily. Control treatments with a 
mutagenic agent and with V79 cells that were not treated by plasma or any agent 
clearly show that CAP produced by the SMD device does not evoke mutations 
beyond naturally occurring spontaneous mutations in V79 cells. 
This was an important finding as the MiniFlatPlaSter, a representative for CAP 
devices based on the SMD technology, now proved its bactericidal efficacy and the 
results of the HPRT assay paved the way to clinical studies. 
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Towards designed plasma and a “therapeutic window” –  
CAP and wound healing  
During the first stage of wound repair – inflammation - microbes are inactivated via 
reactive oxygen species (among others). [117]  
Most of the microorganisms have a limited tolerance for oxygen. This property is 
most evident in the case of obligate anaerobes and microaerophiles, which cannot 
grow in air saturated media, but it is also true for committed aerobes, which grow 
poorly or die when they are exposed to hyperoxia. [53] Some immune cells which 
use the NADPH oxidase enzyme, upon invasion by pathogenic bacteria, also exploit 
oxidative stress as a weapon during phagocytosis. And recently evidence was 
reported that the bactericidal effects of antibiotics with different sites of action rely, in 
part, on the elevation in ROS that they elicit. [118]  
The second stage of wound repair — new tissue formation — occurs 2–10 days 
after injury and is characterized by cellular proliferation and migration of different cell 
types. [117, 119] These immune cells and all cell types that are involved in wound 
healing - platelets, inflammatory cells, fibroblasts and epithelial cells - are also 
capable of producing nitric oxide (NO), either constitutively or in response to 
inflammatory cytokines. [61, 120] Among its many effects, NO plays a critical role in 
host defence by clearing the wound of infectious microbes and stimulating other 
healing factors to access the wound area by maintaining a constant blood flow. [60]  
Various groups are working with methods to deliver NO to chronic wounds to 
improve wound healing and accelerate wound closure. The antimicrobial property of 
NO is also notable in this context which obviously can also be of interest for wound 
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healing. [121, 122] However, the question regarding the optimal dose needed for 
these different modes of action still remains unanswered. Also application forms, 
from topical application of ointments to gaseous NO, are tested. [57, 121, 123, 124]  
But nevertheless the dominant element that seems to be responsible for the 
bactericidal effect of CAP is oxygen or rather reactive oxygen species. [35] The cold 
atmospheric plasma device that was used for the examination of the safety of CAP 
on primary fibroblasts was operated mainly in the ozone based mode (Figure 11).  
Dermal fibroblasts were slowed down in their migration speed and partially inhibited 
in proliferation. But the analysis of the cell cycle distribution and long-time 
observation of the migration showed that those effects only persist for treatment 
times above 90 s. 
Other studies with CAP also dealt with migration and cell cycle distribution. 
Although subject of those investigations were mostly cancer cells, it is noticeable that 
here the decrease in migration speed as well as a G2 / M phase arrest were much 
more dominant, already with lower plasma doses than in our study. [125-127] Also 
the persistence of the arrest was up to several days. [125] 
Arndt et al. [128] could even show improved wound healing in vitro and in vivo on a 
mouse model with punch biopsies. Additionally they suggest senescence as a 
probable effect of CAP on melanoma cells [129] which could be a possible hint 
towards selectivity of CAP. Also important and already shown by for example 
Daeschlein et al. [130] is that CAP is well tolerated by skin and does not harm the 
natural skin flora. Not in the focus of the study but a passing reference of our study 
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with two different handheld devices was that volunteers had no negative side effects 
after the plasma application of their arms or the skin respectively. [131] 
All observed effects – on prokaryotes as well as on eukaryotes - were enhanced by 
increasing plasma dose or treatment time respectively (for example [41, 77, 109, 
132-134]). But microorganisms seem to be much more susceptible towards the 
reactive species produced by cold atmospheric plasma than normal human cells 
which we could show in our own studies (Figure 27 and Figure 28) and what can be 
seen in literature. [6, 10, 15, 135] The decisive point is to find the “therapeutic 
window” where pathogens are already inactivated and normal human cells are not 
yet harmed. Table 5 gives a short summary of all studies that were carried out with 
SMD devices to investigate the bactericidal efficacy as well as the safety of CAP 
application on human skin.  
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Table 5: Results of different studies with different SMD devices to assess the bactericidal 
efficacy and the safety upon dermal cells.  
Power 
consumption 
Treatment time Summary 
20 mW/cm² 20 seconds D. radiodurans and MRSA could be reduced 5 log 
steps by applying CAP for 20 seconds with the 
FlatPlaSter 2.0. 
20 mW/cm² 90 seconds Results of this study show that there is no long 
term damage to primary human dermal fibroblasts 
when treated with the FlatPlaSter 2.0 for up to 90 
seconds. 
35 mW/cm² 15 seconds 
30 seconds 
Treatment of S.aureus with the FlatPlaSter 2.0 on 
agar resulted in a 5.5 log reduction after 15 
seconds. After 30 seconds a 5 log reduction of 
MRSA and many other microorganisms of clinical 
interest was achieved. [7]  
20 mW/cm² 
500 mW/cm² 
20 minutes HE staining of histological samples of plasma 
treated ex vivo skin with FlatPlaSter 2.0 and 
MiniFlatPlaSter showed no damage after 
treatment times up to 20 minutes. [14] 
500 mW/cm² 30 seconds Human skin on the forearm of volunteers was 
inoculated with bacteria and treated with two 
different handheld plasma devices (direct and 
indirect electrodes). After 30 seconds a 2.5 log 
reduction was achieved and no visible damage to 
the skin could be detected. [131] 
500 mW/cm² 60 seconds Immunohistochemical γ-H2AX staining of the ex 
vivo skin samples showed that plasma treatments 
up to 60 s could be considered as a safe 
application time using MiniFlatPlaSter. [14] 
500 mW/cm² 60 seconds A bacterial reduction of up to 3 log steps was 
achieved after 60 seconds of plasma treatment of 
in vitro porcine skin samples inoculated with 
bacteria. [6] 
500 mW/cm² 240 seconds The HPRT assay with V79 Chinese hamster lung 
fibroblasts revealed no mutagenicity after 
treatment with the MiniFlatPlaSter for treatment 
times up to 240 seconds. [69] 
500 mW/cm² 15 minutes The TUNEL staining of skin sections after plasma 
treatment of skin samples inoculated with bacteria 
revealed no damage to intact porcine skin in vitro. 
[6] 
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The shift from mainly ozone (generated at low power input) to nitrogen oxides 
(produced at high power input) that can be observed is a first step towards 
“designed” SMD plasmas dependent to their field of application - wound healing, 
sterilization or cancer treatment. Reactive oxygen species are bactericidal, but: by 
adjusting the SMD plasma at certain power levels ozone will be quenched and 
converted into nitrogen oxides as described above. [35]  
Nitrogen oxides will be further converted to nitric acid or nitrous acid in ambient air 
when trace amount of water vapour is present. In return these species could then 
serve as a source for NO molecules, which are known to stimulate wound healing. 
[57, 59, 60, 121, 123, 124, 136, 137] Studies with nitric oxide-releasing nanoparticles 
already demonstrated accelerated wound healing by promoting fibroblast migration 
and collagen deposition. [59] 
Therefore it is possible to find the exact “therapeutic window” depending on the 
application purpose (Figure 34).  
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Figure 34: The graph shows the power settings and treatment times of several experiments 
that were performed with different SMD devices. The yellow area marks the antimicrobial field 
and the red circuit marks the area where dermal cells and skin are still healthy, a so called 
“therapeutic window”. 
In the example of wounds it would be imaginable to apply plasma with higher power 
first to reduce the bacterial load (the produced ozone can therefore inactivate the 
exposed bacteria within a few seconds) followed by treatment with SMD plasma 
ignited for power consumptions around 0.2 W/cm2 in a confined volume to support 
wound healing and accelerate wound closure.  
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7. Outlook 
Bacteria and other pathogens do not only disturb wound healing, they are 
responsible for other skin diseases as well. A few of them were already part of 
studies with CAP. 
Positive track records could already be achieved in the therapy of herpes zoster. 
Herpes zoster is an acute skin disease due to varicella-zoster virus, a neurotropic 
human alpha-herpes virus and widespread in the population; the global median 
incidence of zoster is estimated to be 4 – 4.5 per 1000 person years, a lifetime risk of 
30%. Incidence and severity rises with increasing age. Among persons older than 80 
years, the incidence is 12.0 per 1000 years. [138, 139] First clinical trials with CAP 
treatment relieved acute pain and accelerated healing. [140] Single case reports give 
a hint that there are many of diseases where CAP could be an option. CAP was able 
to control local infection and reduce pain in a patient with chronic post-operative ear 
infection and lesions in Hailey-Hailey disease were successfully treated. [141, 142] 
Dentistry is also a very promising field for the application of CAP because biofilms 
of for example S. mutans, which play a major role in the pathogenesis of peri-implant 
mucositis [143] have been successfully removed by different non-thermal plasma 
devices. This is also very promising for normal dental hygiene. 
There are many future application fields for CAP – sooner or later. The possible 
treatment of cancer is already envisioned. First studies and mouse models showed 
promising results. [33, 38, 41, 125, 144, 145] And also in this field, designing the 
plasma is crucial. Here the “therapeutic window” depicts a frame where cancer cells 
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can selectively be ablated and the normal surrounding tissue remains unaffected. 
First attempts into this direction were made. [134]  
Nevertheless until CAP will be implemented in clinical applications on human 
tumours is reality, a long way lies ahead. What seems to lie in near future is to 
disinfect wounds or surfaces. All work that was done in this study clearly points the 
way to the future where cold atmospheric plasma could be a medical tool in many 
fields, wound healing as one of them. 
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